Showing 781-790 of 8790 results for "".
Mycosis Fungoides: Practical Tips on Specific Therapies
https://practicaldermatology.com/topics/general-topics/mycosis-fungoides-practical-tips-on-specific-therapies/21973/With common sense and knowledge of the therapy being administered, the dermatologist can effectively and safely treat MF patients.Physician Dispensing: 7 Things Doctors Need to Know
https://practicaldermatology.com/topics/practice-management/physician-dispensing-7-things-doctors-need-to-know/23350/Physician dispensing provides a service to the patient while enhancing the practice. Here’s what you need to know.Update on TB Screening Prior To and During Biologic Treatment
https://practicaldermatology.com/columns/clinical-focus-1/update-on-tb-screening-prior-to-and-during-biologic-treatment/23220/Is annual screening in all patients really neccesary?Guiding Parents Through A Safe and Effective Pediatric Skincare Routine
https://practicaldermatology.com/topics/pediatric/guiding-parents-through-a-safe-and-effectivepediatric-skincare-routine/23081/A snapshot of critical information you’ll need at the ready when it comes time to make a recommendation for your pediatric patients.The Great Imitator: Pruritic Papules in the Setting of HIV
https://practicaldermatology.com/topics/clinical-case-reports/great-imitator-pruritic-papules-setting-hiv/26953/The Great Imitator: Pruritic Papules in the Setting of HIVPhio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.5 Steps to Creating a 5-star Patient Experience
https://practicaldermatology.com/topics/practice-management/5-steps-to-creating-a-5-star-patient-experience/23660/How to ensure the most positive patient experience possible.Pediatric Derm: Sunscreen and Insect Repellent Safety
https://practicaldermatology.com/conferences/aad-summer-2021/pediatric-derm-sunscreen-and-insect-repellent-safety/19973/Parents of pediatric dermatology patients often have lots of questions when it comes to sunscreen safety, especially in light of recent headlines about recalls and absorption concerns. Mercedes Gonzalez, MD offers tips for answering these burning questions, including knowing how to discuss availableOf Fitness, Friction, Fillers, and Fat: Pearls for Managing Active Patients
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/of-fitness-friction-fillers-and-fat-pearls-for-managing-active-patients/23531/Help physically fit patients look as good as they feel.